Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A DNA immunotherapy could spare women from surgery for precancerous cervical lesions. In a phase 3 trial, VGX-3100 achieved histologic regression and HPV-16/18 clearance in 52.5% of patients vs. 35.3% on placebo — a meaningful difference with a strong safety profile. Researchers say it could become a viable nonsurgical alternative for managing HPV-driven cervical disease.
A DNA immunotherapy called VGX-3100 has shown significant promise in treating precancerous cervical lesions caused by HPV-16 and HPV-18 — without surgery. In the phase 3 HPV-303CHN trial, the drug met its primary endpoint, achieving both lesion regression and viral clearance in over half of treated patients, compared to about a third of those on placebo.
The trial enrolled 207 patients in China with high-grade squamous intraepithelial lesions (HSILs) — a serious precancerous condition. VGX-3100 targets the HPV E6 and E7 oncoproteins to trigger T-cell immune responses against the virus. It's delivered via intramuscular injection followed by electroporation, and was well tolerated, with no serious treatment-related adverse events reported.
By the Numbers:
Why it matters: Current standard care for cervical HSILs involves surgical excision, which removes the lesion but not the virus and carries risks of adverse obstetric outcomes. VGX-3100 could offer a nonsurgical path that addresses the root cause — particularly valuable for younger women hoping to preserve fertility.
